



DRUG REVIEW



October 2021

Energair Breezhaler® - Boosting Adherence to Improve Asthma Outcomes

Asthma is a very common chronic breathing condition seen in patients of all ages and backgrounds. Asthma involves inflammation of the airways that leads to limited airflow and difficulty breathing. Symptoms of asthma include chest tightness, wheezing, coughing and breathlessness. Asthma has a significant burden on an individual physically, psychologically, and socially. In Canada, approximately 8.3% of patients suffer from asthma, and it continues to be one of the most common chronic conditions in the world.

The goal of asthma treatment is to limit the symptoms and improve breathing. The treatment of asthma usually involves a low dose-inhaled corticosteroid (ICS) that is intended for symptom control. If symptoms are still unmanaged, then a maintenance inhaler containing a long-acting beta agonist (LABA) is introduced. If asthma remains uncontrolled, then either a long-acting muscarinic antagonist (LAMA) or a leukotriene receptor antagonist (LTRA) is added on. Due to the cumulative nature of asthma treatment, regimens can become complicated, resulting in misuse of inhalers and lack of adherence. Non-adherence is one of the leading causes of uncontrolled asthma. Currently there are no products available that deliver a combination of LABA, LAMA and ICS; therefore, multiple inhalers are often necessary.

Energair Breezhaler® is a once-daily, fixed dose combination LABA/LAMA/ICS inhaler for the treatment of uncontrolled asthma. Energair Breezhaler® provides a treatment option that can boost adherence by eliminating the need for multiple inhalers, which will lead to better overall outcomes for patients.

Energair Breezhaler® provides a simple and effective treatment option for patients with uncontrolled asthma. The annual cost of \$1,234 makes Energair Breezhaler® more cost effective than the combination of the alternative LABA/ICS plus LAMA inhalers. For these reasons, Energair Breezhaler® will be Fully Covered for both Managed and Open Formularies.

| | |
|------------------|---|
| Drug Name | Energair Breezhaler® |
| Drug Ingredients | Indacaterol/Glycopyrronium /Mometasone |
| Annual Cost | \$1,234 |
| Coverage Details | Fully Covered for Managed and Open formularies |

ClaimSecure Inc. reserves the right to amend in part, or in its entirety, its Special Authorization guidelines.

References:

1. Energair Breezhaler® Product Monograph. Novartis Pharmaceuticals Canada Inc. July 2020.
2. Global Initiative for Asthma – Global Strategy for Asthma Management and Prevent, 2021. <https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf>

©2021 ClaimSecure Inc.

